Amarin scores a big win for its cardio outcomes study on Vascepa — stock races higher as analysts applaud
Amarin $AMRN has staked its claim to the next big blockbuster in the cardio space, heralding a clear statistical win on the primary endpoint for its 7-year clinical quest to prove that its industrial strength purified fish oil Vascepa can significantly reduce major cardio threats for a broad swath of patients.
An early preview of the top-line data rolled out at a bleary-eyed time in the morning on Monday pointed a direct arrow at a relative 25% drop in risk for major cardio events — such as death, stroke and hospitalization due to angina — hitting a highly statistical p=<0.001 for the patients in the years-long REDUCE-IT study. And researchers also high-fived each other for a clean safety profile in the same headline data to make the statement.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.